Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

98.14 +0.86 (+0.88%)
Streaming Delayed Price Updated: 2:09 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,250,045
Open 98.50
Bid (Size) 98.13 (6)
Ask (Size) 98.14 (1)
Prev. Close 97.28
Today's Range 97.41 - 98.55
52wk Range 92.19 - 108.78
Shares Outstanding N/A
Dividend Yield 3.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Novartis Stock Topped the Market on Tuesday
A double beat on the latest quarterly results and raised guidance made investors happy. 
Via The Motley Fool
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating this rare cancer. Explore its efficacy in combating SSTR+ tumors, backed by... 
Via Benzinga
Exposures Product Safety

Performance

YTD
-2.84%
-2.84%
1 Month
+2.51%
+2.51%
3 Month
-8.91%
-8.91%
6 Month
+3.40%
+3.40%
1 Year
-2.44%
-2.44%

More News

Read More
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise
Via Investor's Business Daily
Looking At Novartis's Recent Unusual Options Activity
Via Benzinga
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Via Benzinga
Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback'
Via Benzinga
Topics Bonds
Exposures Debt Markets
Top Analyst Reports For Novartis, American Express & ConocoPhillips
Via Talk Markets
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
Via Investor's Business Daily
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Via Benzinga
Exposures Product Safety
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
Via Benzinga
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
Via The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Via Benzinga
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
Via The Motley Fool
Topics ETFs
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Via Benzinga
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Via Investor's Business Daily
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
Via Benzinga
SOUN Stock Alert: The $150 Million Reason SoundHound AI Is Down Today
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Jack Ma Is Giving Alibaba (BABA) Stock a Big Boost
Via InvestorPlace
Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.